214 related articles for article (PubMed ID: 17121756)
1. Inhibition of CETP as a novel therapeutic strategy for reducing the risk of atherosclerotic disease.
Shah PK
Eur Heart J; 2007 Jan; 28(1):5-12. PubMed ID: 17121756
[TBL] [Abstract][Full Text] [Related]
2. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
Hausenloy DJ; Yellon DM
Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
[TBL] [Abstract][Full Text] [Related]
3. [HDL and CETP in atherogenesis].
Pöss J; Böhm M; Laufs U
Dtsch Med Wochenschr; 2010 Feb; 135(5):188-92. PubMed ID: 20082258
[TBL] [Abstract][Full Text] [Related]
4. HDL metabolism and CETP inhibition.
Barkowski RS; Frishman WH
Cardiol Rev; 2008; 16(3):154-62. PubMed ID: 18414186
[TBL] [Abstract][Full Text] [Related]
5. Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease.
Barter PJ; Kastelein JJ
J Am Coll Cardiol; 2006 Feb; 47(3):492-9. PubMed ID: 16458126
[TBL] [Abstract][Full Text] [Related]
6. The potential for CETP inhibition to reduce cardiovascular disease risk.
Ansell B; Hobbs FD
Curr Med Res Opin; 2006 Dec; 22(12):2467-78. PubMed ID: 17257461
[TBL] [Abstract][Full Text] [Related]
7. HDL-cholesterol: is it really good? Differences between apoA-I and HDL.
Santos-Gallego CG; Ibanez B; Badimon JJ
Biochem Pharmacol; 2008 Aug; 76(4):443-52. PubMed ID: 18547543
[TBL] [Abstract][Full Text] [Related]
8. Increasing high-density lipoprotein cholesterol, inhibition of cholesteryl ester transfer protein, and heart disease risk reduction.
Schaefer EJ; Asztalos BF
Am J Cardiol; 2007 Dec; 100(11 A):n25-31. PubMed ID: 18047849
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease.
Chapman MJ
Pharmacol Ther; 2006 Sep; 111(3):893-908. PubMed ID: 16574234
[TBL] [Abstract][Full Text] [Related]
10. Lessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial.
Barter P
Am J Cardiol; 2009 Nov; 104(10 Suppl):10E-5E. PubMed ID: 19895939
[TBL] [Abstract][Full Text] [Related]
11. Dalcetrapib: a review of Phase II data.
Robinson JG
Expert Opin Investig Drugs; 2010 Jun; 19(6):795-805. PubMed ID: 20465364
[TBL] [Abstract][Full Text] [Related]
12. Refocusing on use of cholesteryl ester transfer protein inhibitors.
Kastelein JJ
Am J Cardiol; 2007 Dec; 100(11 A):n47-52. PubMed ID: 18047853
[TBL] [Abstract][Full Text] [Related]
13. Where are we with high-density lipoprotein raising and inhibition of cholesteryl ester transfer for heart disease risk reduction?
Schaefer EJ; Asztalos BF
Curr Opin Cardiol; 2007 Jul; 22(4):373-8. PubMed ID: 17556892
[TBL] [Abstract][Full Text] [Related]
14. CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction.
Regieli JJ; Jukema JW; Grobbee DE; Kastelein JJ; Kuivenhoven JA; Zwinderman AH; van der Graaf Y; Bots ML; Doevendans PA
Eur Heart J; 2008 Nov; 29(22):2792-9. PubMed ID: 18957472
[TBL] [Abstract][Full Text] [Related]
15. Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion.
Kappelle PJ; van Tol A; Wolffenbuttel BH; Dullaart RP
Cardiovasc Ther; 2011 Dec; 29(6):e89-99. PubMed ID: 20645987
[TBL] [Abstract][Full Text] [Related]
16. CETP inhibition in cardiovascular risk management: a critical appraisal.
Dullaart RP; Dallinga-Thie GM; Wolffenbuttel BH; van Tol A
Eur J Clin Invest; 2007 Feb; 37(2):90-8. PubMed ID: 17217373
[TBL] [Abstract][Full Text] [Related]
17. Raising high-density lipoprotein with cholesteryl ester transfer protein inhibitors.
Clark RW
Curr Opin Pharmacol; 2006 Apr; 6(2):162-8. PubMed ID: 16487747
[TBL] [Abstract][Full Text] [Related]
18. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
Abdel-Maksoud M; Sazonov V; Gutkin SW; Hokanson JE
J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276
[TBL] [Abstract][Full Text] [Related]
19. Is high HDL cholesterol always good?
Olsson AG
Ann Med; 2009; 41(1):11-8. PubMed ID: 19085339
[TBL] [Abstract][Full Text] [Related]
20. Cholesteryl ester transfer protein (CETP) inhibitors: is there life after torcetrapib?
Neeli H; Rader DJ
Cardiol Clin; 2008 Nov; 26(4):537-46. PubMed ID: 18929230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
